Table 1. Characteristics of included studies.
| Authors | Year | Bipolarequipment | No ofpatients | Max. followup (months) | Age(years) | Prostatevolume(ml) | IPSS | QoL | Qmax(ml/s) | PVR (ml) | IIEF |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yang et al.19 | 2004 | PK | 58/59 | 3 | NA | 45.8/48.9 | 20.9/21.6 | 3.7/4.0 | 10.4/10.9 | 99.0/150.0 | 8.2/7.8 |
| Akcayoz et al.20 | 2006 | PK | 21/21 | NA | 67.0/66.0 | 40.0/47.0 | NA | NA | NA | NA | NA |
| Kim et al.22 | 2006 | PK | 25/25 | 6 | 68.1/70.6 | 51.7/53.2 | 19.0/18.6 | NA | 6.5/6.1 | NA | NA |
| Nuhoglu et al.23 | 2006 | PK | 27/30 | 12 | 64.6/65.2 | 47.0/49.0 | 17.6/17.3 | NA | 6.9/7.3 | 96.0/88.0 | NA |
| Patankar et al.24 | 2006 | PK | 52/51 | 1 | 64.0/62.0 | 51.3/52.3 | 23.3/23.7 | NA | 5.9/6.4 | NA | NA |
| Seckiner et al.25 | 2006 | PK | 24/24 | 12 | 61.2/63.9 | 49.4/41.4 | 24.1/23.2 | NA | 8.5/8.3 | NA | NA |
| Erturhan et al.27 | 2007 | PK | 120/120 | 12 | 68.5/67.4 | 43.0/42.0 | 23.0/24.0 | 2.0/3.0 | 10.9/9.2 | NA | NA |
| Iori et al.28 | 2008 | PK | 27/26 | 12 | 65.0/63.0 | 49.0/48.0 | 21.0/20.0 | 3.0/3.6 | 7.0/8.7 | 99.0/96.0 | NA |
| Kong et al.31 | 2009 | PK | 51/51 | 12 | 68.4/68.5 | 41.8/43.1 | 23.3/23.9 | 4.5/4.5 | 4.99/4.60 | 107.0/103.0 | NA |
| Bhansali et al.30 | 2009 | PK | 35/35 | 9 | NA | 78.5/78.7 | NA | NA | 4.4/4.2 | NA | NA |
| Autorino et al.21,26,29 | 2009 | PK | 35/35 | 48 | 61.0/59.0 | 47.5/51.6 | 24.3/24.2 | 3.9/4.2 | 6.2/7.1 | 75.0/80.0 | NA |
| Singhania et al.32 | 2010 | PK | 30/30 | 12 | 63.9/65.9 | 40–80 | 24.1/23.4 | NA | 6.6/6.4 | NA | NA |
| Xie et al.34 | 2012 | PK | 110/110 | 60 | 69.9/64.9 | 65.9/67.0 | 23.8/22.8 | 4.5/4.4 | 9.8/9.7 | 94.5/96.3 | NA |
| Huang et al.33 | 2012 | PK | 71/65 | NA | 65.1/64.6 | 52.9/50.1 | 23.4/22.1 | 4.2/4.1 | 6.7/6.9 | NA | NA |
| Giulianelli et al.35 | 2013 | PK | 80/80 | 36 | 62.5/64.2 | 47.8/50.0 | 22.3/23.4 | 3.3/3.0 | 8.9/6.5 | 243.0/187.0 | 16.0/17.0 |
| Kumar et al.36 | 2013 | PK | 57/60 | 12 | 62.3/63.7 | 50.3/52.2 | 19.8/20.7 | 3.6/3.7 | 7.1/7.0 | 148.4/139.3 | 17.3/17.0 |
PK; Plasmakinetic system, IPSS; International Prostate Symptom Score, Qmax; maximum flow rate, QoL; quality of life, PVR; post-void residue, IIEF; International Index for Erectile Function, NA; not available.